The study results, published in The New England Journal of Medicine (NEJM Vol. 362 No. 25), also demonstrated cost savings in use of the fractional-dose intradermal injection as compared with a full-dose vaccination course of treatment using an auto-disable needle and syringe.
Bioject Medical Technologies said that the study was conducted in Oman and as part of the Global Polio Eradication Initiative (GPEI), the study was supported by the Ministry of Health of Oman, the Program for Appropriate Technology in Health (PATH) and the World Health Organization (WHO).
The study is a randomised clinical trial in which the intradermal fractional-dose was given with its B2000 needle-free injection delivery device and the full-dose was delivered with an auto-disable syringe and needle.
Richard Stout, executive vice president and chief medical officer of Bioject, said: “We are pleased to have participated in this clinical trial and to learn about the positive results with intradermal fractional-dose injection of inactivated polio vaccine using Bioject’s intradermal delivery technology.
“We look forward to working with other organisations who are interested in leveraging the benefits of our needle-free intradermal injection delivery technology for their vaccine portfolios.”